<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071993</url>
  </required_header>
  <id_info>
    <org_study_id>15097</org_study_id>
    <nct_id>NCT01071993</nct_id>
  </id_info>
  <brief_title>Efficacy of Statins In Prevention of CIN</brief_title>
  <acronym>SCIN</acronym>
  <official_title>Efficacy Of Statins In The Prevention of Contrast-Induced Nephropathy in Patients With Chronic Renal Insufficiency (SCIN Trial): A Double-Blind, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if statin therapy plus intravenous normal saline, in patients with chronic renal
      insufficiency undergoing angiography, is superior to placebo plus intravenous normal saline
      therapy in the prevention of CIN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to the conflict in the available data, there are no practice guidelines that are
      established in order to prevent contrast-induced nephropathy (CIN). Our goal is to determine
      if statin therapy plus intravenous normal saline, in patients with chronic renal
      insufficiency undergoing angiography, is superior to placebo plus intravenous normal saline
      therapy in the prevention of CIN.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor can not supply drugs anymore.
  </why_stopped>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoint. Development of CIN (Contrast-induced Nephropathy) Defined as a Postprocedure Increase in Serum Creatinine of &gt; 0.5 mg/dL or &gt;25% Increase From Baseline at 24 &amp; at 48 Hours.</measure>
    <time_frame>48 hours</time_frame>
    <description>Development of CIN (Contrast-induced Nephropathy) Defined as a Postprocedure Increase in Serum Creatinine of &gt; 0.5 mg/dL or &gt;25% Increase From Baseline at 24 &amp; at 48 Hours</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Nephropathy</condition>
  <arm_group>
    <arm_group_label>atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>pre-treatment with placebo (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>pre-treatment with atorvastatin (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)</description>
    <arm_group_label>atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Inclusion Criteria:

               -  Adults &gt; 18 years of age

               -  undergoing coronary or peripheral angiography with or without intervention

               -  Cr &gt; 1.3 mg/dL or GFR &lt; 60 mL/min

          2. Exclusion Criteria:

               -  end-stage renal disease on dialysis

               -  acute renal failure

               -  previous iodinated contrast media exposure within 7 days of study entry

               -  history of hypersensitivity to statins

               -  pregnancy or lactation

               -  emergent coronary angiography, ST elevation myocardial infarction (STEMI), or
                  cardiogenic shock

               -  prisoners

               -  patients already on maximum dose of statins

               -  patient receiving N-acetylcysteine or sodium bicarbonate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mazen Abu-Fadel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oklahoma Univeristy Health Science Center and VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oklahoma University Health Science Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <results_first_submitted>April 7, 2017</results_first_submitted>
  <results_first_submitted_qc>August 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2017</results_first_posted>
  <last_update_submitted>October 27, 2017</last_update_submitted>
  <last_update_submitted_qc>October 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevention</keyword>
  <keyword>nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No data was collected; therefore, a plan is not applicable.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited and signed consent. No drugs were supplied to participants. Study sponsor could not provide study drugs to participants due to cost restraints.</recruitment_details>
      <pre_assignment_details>Prior to assigning participants to specific arms of the protocol, site was informed that the study drug was no longer available.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin</title>
          <description>atorvastatin: pre-treatment with atorvastatin (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo: pre-treatment with placebo (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants signed consent; however, study was terminated prior to randomization.</population>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin</title>
          <description>atorvastatin: pre-treatment with atorvastatin (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo: pre-treatment with placebo (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Endpoint. Development of CIN (Contrast-induced Nephropathy) Defined as a Postprocedure Increase in Serum Creatinine of &gt; 0.5 mg/dL or &gt;25% Increase From Baseline at 24 &amp; at 48 Hours.</title>
        <description>Development of CIN (Contrast-induced Nephropathy) Defined as a Postprocedure Increase in Serum Creatinine of &gt; 0.5 mg/dL or &gt;25% Increase From Baseline at 24 &amp; at 48 Hours</description>
        <time_frame>48 hours</time_frame>
        <population>Participants signed consent; however, study was terminated prior to randomization</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>atorvastatin: pre-treatment with atorvastatin (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: pre-treatment with placebo (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Endpoint. Development of CIN (Contrast-induced Nephropathy) Defined as a Postprocedure Increase in Serum Creatinine of &gt; 0.5 mg/dL or &gt;25% Increase From Baseline at 24 &amp; at 48 Hours.</title>
          <description>Development of CIN (Contrast-induced Nephropathy) Defined as a Postprocedure Increase in Serum Creatinine of &gt; 0.5 mg/dL or &gt;25% Increase From Baseline at 24 &amp; at 48 Hours</description>
          <population>Participants signed consent; however, study was terminated prior to randomization</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Not applicable/study was terminated prior to randomization.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin</title>
          <description>atorvastatin: pre-treatment with atorvastatin (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo: pre-treatment with placebo (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study Sponsor no longer supplied study drug/placebo.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mazen Abu-Fadel, MD</name_or_title>
      <organization>University of Oklahoma</organization>
      <phone>405-271-4742</phone>
      <email>mazen-abufadel@ouhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

